State of the art in the delivery of photosensitizers for photodynamic therapy

Journal of Photochemistry and Photobiology B: Biology

Volumn 66, Issue 2, 2002, Pages 89-106

  Konan, Yvette Niamien ^a   Gurny, Robert ^a   Allémann, Eric ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Active targeting systems; Drug delivery systems; Passive targeting vehicles; Photodynamic therapy; Photosensitizers; Review

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CASTOR OIL; CHLOROALUMINUM PHTHALOCYANINE; CREMOPHOR; DIMETHYL SULFOXIDE; DIOLEOYLPHOSPHATIDYLSERINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; GAMMA CYCLODEXTRIN; GERMANIUM DERIVATIVE; HEMATOPORPHYRIN DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LIPOSOME; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; MONOCLONAL ANTIBODY; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; OIL; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PHTHALOCYANINE ZINC; POLYMER; POLYSORBATE 80; POLYVINYL ALCOHOL; PORPHYRIN DERIVATIVE; PURPURIN; TALAPORFIN; TRITON X 100; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL TISSUE; CANCER; COLLOID; CONTROLLED STUDY; DISPERSION; DRUG ACCUMULATION; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; ENCAPSULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; LIPOPHILICITY; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RAT; REVIEW; SIDE EFFECT; SURFACE PROPERTY; TUMOR;

EID: 0036496275     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1011-1344(01)00267-6     Document Type: Article

References (151)

1. New applications in photodynamic therapy introduction
2. Photosensitizers, therapy and detection of malignant tumors
3. The use of a derivative of hematoporphyrin in tumour detection
4. Photoradiation therapy II. Cure of animal tumours with haematoporphyrin and light
5. Photoradiation therapy for the treatment of malignant tumours
6. Photodynamic therapy of malignant tumours
7. Skin photosensitivity: Duration and intensity following intravenous hematoprohyrin derivatives, HPD and DHE
8. Modified porphyrins, chlorins, phthalocyanines, and purpurins: Second generations photosensitizers for photo-dynamic therapy
9. Biological activities of phthalocyanines-IX. Photosensitzation of V-79 chinese hamster cells and EMT-6 mouse mammary tumor by selectively sulfonated zinc phthalocyanines
10. Phthalocyanine as photodynamic sensitizers
11. A new in vitro technique for the evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure
12. Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A
13. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: Initial results
14. Accumulation of porphyrins in cells: Influence of hydrophobicity aggregation and protein binding
15. Site-specific (targeted) drug delivery in cancer therapy
16. Prospects of phthalocyanines as photosensitizers for the photodynamic therapy of cancer
17. Pharmacokinetics and body distribution of liposomal zinc phthalocyanine in tumor-bearing mice: Influence of aggregation state, particle size, and composition
18. Structure and biodistribution relationships of photodynamic sensitizers
19. Approaches to targetted photodynamic tumor therapy
20. Role of delivery vehicles for photosensitizers in the photodynamic therapy of tumors
21. Photosensitization: Reaction pathways
22. Spectroscopic studies and photodynamic actions of hypocrellin B in liposomes
23. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions
24. Intratumoural distribution as a determinant of tumour responsiveness to therapy using polymer-based macromolecular prodrug
25. Drug targeting: Where are we now and where are we going?
26. Liposomal drug delivery: Possibilities for manipulation
27. Pharmacokinetics, tissue distribution and photodynamic therapy efficacy of liposomal-delivered hypocrellin A, a potential photosensitizer for tumor therapy
28. Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes
29. Increase of photosensitizing efficiency of the bacteriochlorin a by liposomes-incorporation
30. Controlled targeting of different subcellular sites by porphyrin in tumour-bearing mice
31. Liposomal delivery of a photosensitizer benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model
32. Fluorescence absorption and electron spin resonance study of bacteriochlorin a incorporation into membrane models
33. Large-scale production of liposomes containing monomeric zinc phthalocyanine by controlled dilution of organic solvents
34. CGP 55398, a liposomal Ge(IV) phthalocyanine bearing two axially ligated cholesterol moities: A new potential agent for photodynamic therapy of tumours
35. In vivo fluorescence and photodynamic activity of zinc phthalocyanine administered in liposomes
36. Photodynamic therapy: A novel approach to treat variety of diseases
37. Liposomal benzoporphyrin derivate verteporfin photodynamic therapy: Selective treatment of choroidal neovascularization in monkeys
38. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related degeneration
39. Treatment of subfoveal choroidal neovascularisation in age related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy
40. Photodynamic therapy of subfoveal choproidal neovascularization in age reacted macular degeneration with verteporfin: 2-year results of two randomized clinical trials-tap report-2
41. A dose response analysis of purpurin derivatives used as photosensitizers for the photodynamic treatment of transplantable fanft induced urothelial tumors
42. New photosensitiers for photodynamic therapy: Combined effect of metallopurpurin derivatives and light on transplantable bladder tumors
43. Effect of delivery system on the pharmacokinetic and phototherapeutic properties of bis(methyloxyethyleneoxy) silicon-phthalocyanine in tumor-bearing mice
44. Sites and efficacy of photodamage by tin etiopurpurin in vitro using different delivery systems
45. The use of liposomes, emulsions or inclusion complexes may potentiate in vivo effects of SnET2
46. Binding of drugs to human plasma proteins, exemplified by Sn(IV)-etiopurpurin dichloride delivered in cremophor and DMSO
47. The alteration of plasma lipoproteins by cremophor EL
48. Suspected anaphylactic reaction to cremophor EL
49. Methods for preventing reactions secondary to cremophor EL
50. Anaphylactoid reactions associated with parenteral cyclosporine use: Possible role of cermophor EL
51. Pharmacology and toxicology of cremophor EL diluent
52. Polymeric micelles: A new generation of colloidal drug carriers
53. Preparation and characterization of pH-responsive polymeric micelles for the delivery of photosensitizing anticancer drugs
54. In-vitro and in-vivo evaluation of pH-responsive polymeric micells in a photodynamic cancer therapy
55. In vivo and in vitro photodynamic studies with benzochlorin imimium salts delivered by a lipid emulsion
56. Biodegradable nanoparticles from sustained release formulations to improved site specific drug delivery
57. Drug targeting in cancer chemotherapy: A clinical perspective
58. Biodegradable nanospheres containing phthalocyanines and naphthtalocyanines for targeted photodynamic tumor therapy
59. Evaluation of nanoparticles as drug-delivery systems III: Materials, stability, toxicity, possibilities of targeting, and use
60. Adsorption of hematoporphyrin onto polyalkylcyanoacrylate nanoparticles: Carrier capacity and drug release
61. A comparative study of the cellular uptake, localization and phototoxicity of metatetra(hydroxyphenyl)chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells
62. Nanocapsules with a reduced liver uptake: Targeting of phthalocyanines to EMT-6 mouse mammary tumour in vivo
63. 6 in the photodynamic therapy of human bladder carcinoma cells
64. PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours
65. 6-conjugated microspheres
66. 6 coupled microspheres
67. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma
68. 6 does not induce p-glycoprotein-mediated multidrug resistance
69. 6) conjugate
70. 6 conjugate in a rat orthotopic prostate tumour
71. In vitro and in vivo spectrofluorometry of a water-soluble meta(tetrahydroxyphenyl)chlorin (m-THPC) derivative
72. Experimental assessment of photodynamic therapy with a poly-ethylene glycol derivative of m
73. Photosensitizing effects of m-tetrahydroxy-phenylchlorin on human tumor xenografts: Correlation with sensitizer uptake, tumor doubling time and tumor histology
74. Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases
75. Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to poly-ethylene gylcol in nude mice grafted with a human colon carcinoma
76. Photodynamic therapy with mTHPC and polyethylene glycol-derived mTHPC: A comparative study on human tumour xenografts
77. Highly selective targeting of ovarian cancer with the photosensitizer PEG-m-THPC in a rat model
78. Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: Photodynamic activities and pharmacokinetics in tumour-bearing mice
79. Biodistribution and bioactivity of tetrapegylated meta-tetra(hydroxyphenyl)chlorin compared to native meta-tetra(hydroxyphenyl)chlorin in a rat liver tumor model
80. Endobronchial photodynamic therapy: Comparison of mTHPC and polyethylene glycol-derived mTHPC on human tumor xenopgrafts and tumor-free bronchi of minipigs
81. mTHPC polymer conjugates: The in vivo photodynamic activity of four candidate compounds
82. Si(IV)naphthalocyanine: Modulation of its pharmacokinetic properties through the use of hydrophilic axial ligands
83. Serum opsonins and liposomes: Their interaction and opsonophagocytosis
84. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs
85. Targeting zinc protoporphyrin liposomes to the spleen using reticuloendothelial blockade with blank liposomes
86. Influence of the steric barrier activity of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
87. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908
88. Photodynamic therapy of tumours with hexadecafluoro zinc phthalocyanine formulated in PEG-coated poly(lactic acid) nanoparticles
89. Long-circulating liposomes: Development and perspectives
90. Microspheres for targeting drugs to specific body sites
91. Anticancer therapy using glucuronate modified long-circulating liposomes
92. Application of long-circulating liposomes to cancer photodynamic therapy
93. Soluble polymers as targetable drug carriers
94. Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo
95. Porphyrin-lipoprotein association as a factor in porphyrin localization
96. Lysosomes, a key target of hydrophobic photosensitizers proposed for photochemotherapeutic applications
97. In vivo assimilation of low density lipoproteins by a fibrosarcoma tumor line in mice
98. Low-density lipoprotein metabolism mice with soft tissue tumours
99. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative
100. The role of lipoproteins in the delivery of tumour-targeting photosensitizers
101. Photodynamic therapy: The clinical perspective
102. Delivery of lipophilic drugs using lipoproteins
103. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement
104. Cellular uptake and photosensitizing properties of anticancer porphyrins in cell membranes and low and high density lipoproteins
105. Uptake of low-density lipoprotein by malignant cells: Possible therapeutic applications
106. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems
107. Photophysical and photobiological processes in the photodynamic therapy of tumours
108. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism
109. Drug targeting: Application of endogenous carriers for site-specific delivery of drugs
110. Assimilation of LDL by experimental tumours in mice
111. In vitro interaction of the photoactive anticancer porphyrin derivate photofrin II with low density lipoprotein, and its delivery to cultured human fibroblasts
112. Role of high, low-and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo
113. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensibilization with benzoporphyrin derivative
114. Vascular targeting in photodynamic occlusion of subretinal vessels
115. Liposome- or LDL-administered Zn(II)-phthalocyanine as a photodynamic agent for tumors. I. Pharmacokinetic properties and phototherapeutic efficiency
116. Photo-dynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates
117. Review: Advances in monoclonal antibody tumour targeting
118. Antibody-targeted drugs for the therapy of cancer
119. Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates
120. Attachment of monoclonal antibodies to microspheres
121. The preparation and application of porphyrin-monoclonal antibodies for cancer therapy
122. Development of technology for linking photosensitizers to a model monoclonal antibody
123. Strategies for selective cancer photochemotherapy: Antibody-targeted and selective carcinoma cell photolysis
124. Biodistribution of charged F(ab')2 photoimmuno-conjugates in a xenograft model of ovarian cancer
125. 6 immunoconjugates
126. Biodistribution of charged 17.4A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer
127. 6 immunoconjugate
128. Development of meta-tetrahydroxyphenylchlorin-monoclonal conjugates for photoimmunotherapy
129. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photdynamic therapy
130. Immunoliposome targeting to pulmonary endothelium
131. The use of drug-loaded nanoparticles in cancer chemotherapy
132. Specific targeting and toxicity of sulphonated aluminium phthalocyanine photosensitised liposomes directed to cells by monoclonal antibody in vitro
133. Possibility of active targeting to tumor tissues with liposomes
134. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model
135. Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer ex vivo
136. Tissue-level transport mechanisms of intraperitoneally-administered monoclonal antibodies
137. Antibody transport in cultured tumor cell layers
138. Passive immunotherapy of cancer: Perspectives and problems
139. 6 selectively potentiates its photodynamic therapy
140. 6 internalizable conjugates on A431 cells
141. Photosensitizer targeting in photodynamic therapy. I. Conjugates of hematoporphyrin with albumin and transferrin
142. 6
143. 6 in human bladder carcinoma cells
144. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative
145. Delivery of benzoporphyrin derivate, a photosensitizer, into atherosclerotic plaque of watanabe heritable hyperlipidemic rabbits and balloon-injured New Zealand rabbits
146. Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation
147. 6 conjugate
148. Monoclonal antibody-chromophore conjugate as selective phototoxins